• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    CHMP Recommends Rybrevant & Lazcluze® for EGFR-mutant NSCLC

    GLOBENEWSWIRE

    J&J Bolsters Rybrevant-Lazcluze Case Vs AZ`s Tagrisso With Survival Data

    FIERCE PHARMA

    RYBREVANT Plus Lazertinib Shows Survival Trend In Lung Cancer

    GLOBENEWSWIRE

    LAZCLUZE Now Available From Onco360 For Metastatic NSCLC Treatment

    GLOBENEWSWIRE

    FDA Roundup: August 20, 2024

    PR NEWSWIRE

    PALOMA-2: Amivantamab/Lazertinib Shows Response, Safety In EGFR+ NSCLC

    PR NEWSWIRE

    PALOMA-2: Subcutaneous RYBREVANT Combo Shows Response, Safety In EGFR+ NSCLC

    GLOBENEWSWIRE

    PALOMA-3: 5-Min Subcut Amivantamab Reduced Infusion Reactions 5-Fold

    PR NEWSWIRE

    RYBREVANT® Plus Lazertinib Shows Longer PFS Vs Osimertinib In EGFR+ NSCLC

    PR NEWSWIRE

    J&J Submits sBLA and NDA to U.S. FDA Seeking Approval of RYBREVANT

    PR NEWSWIRE

    J&J details Tagrisso-topping data for Rybrevant, Leclaza combo

    PR NEWSWIRE

    Landmark Phase 3 MARIPOSA Study Shows RYBREVANT® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer

    PR NEWSWIRE

    J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

    ENDPTS

    Treatment with RYBREVANT and Lazertinib Showed Survival in Advanced NSCLC

    PR NEWSWIRE

    Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy With and Without Lazertinib versus Chemotherapy Alone in Patients with EGFR-Mutated Non-Small Cell Lung Cancer after Disease Progression on Osimertinib

    PR NEWSWIRE

    Janssen Announces Data Supporting Safety and Efficacy of RYBREVANT + Lazertinib

    PRNEWSWIRE

    New Data on RYBREVANT+Lazertinib Show Early Activity in Patients with NSCLC

    PRNEWSWIRE

    Janssen’s Anti-EGFR Combo Tackles Lung Cancer Ahead Of Phase 3 Tagrisso Showdown

    FIERCE BIOTECH

    Yuhan signs $1.25b licensing deal with Janssen for new lung cancer drug

    KOREA HERALD

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.